Cargando…
Phase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Efforts to develop new therapies to combat Alzheimer's disease suffer from extraordinarily high failure rates that make it difficult to justify continued investment in the field. Although there are a number of plausible explanations for this extremely high attrition rate, one of the explanation...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651424/ https://www.ncbi.nlm.nih.gov/pubmed/29067346 http://dx.doi.org/10.1016/j.trci.2017.04.005 |